IMCR

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change +0.27
Percentage change 0.82	%

Peers: MRNA REGN AMGN VRTX BIIB BNTX BMY GILD INCY NVAX

| Held by: IBB SPDW ONEQ GWX SBIO CANC BBP ISCF TMED IBBQ

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.44	Insider Own	3.12%	Shs Outstand	50.18M	Perf Week	3.12%
Market Cap	1.66B	Forward P/E	-	EPS next Y	-1.27	Insider Trans	106.47%	Shs Float	48.62M	Perf Month	-14.54%
Enterprise Value	1.25B	PEG	-	EPS next Q	-0.20	Inst Own	91.68%	Short Float	17.20%	Perf Quarter	12.20%
Income	-21.31M	P/S	4.96	EPS this Y	23.65%	Inst Trans	5.11%	Short Ratio	20.37	Perf Half Y	13.74%
Sales	334.07M	P/B	4.40	EPS next Y	-63.23%	ROA	-2.11%	Short Interest	8.36M	Perf YTD	11.93%
Book/sh	7.50	P/C	1.98	EPS next 5Y	-9.63%	ROE	-5.78%	52W High	41.54 -20.51%	Perf Year	-9.36%
Cash/sh	16.68	P/FCF	63.61	EPS past 3/5Y	37.84% -	ROIC	-2.63%	52W Low	23.15 42.63%	Perf 3Y	-7.27%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	104.15% 56.79%	Gross Margin	97.79%	Volatility	4.40% 4.58%	Perf 5Y	-
Dividend TTM	-	EV/Sales	3.75	EPS Y/Y TTM	64.63%	Oper. Margin	-14.23%	ATR (14)	1.54	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.31	Sales Y/Y TTM	25.50%	Profit Margin	-6.38%	RSI (14)	51.47	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	6.36	EPS Q/Q	119.83%	SMA20	-1.39%	Beta	0.77	Target Price	62.67
Payout	-	Debt/Eq	1.15	Sales Q/Q	33.75%	SMA50	2.46%	Rel Volume	0.30	Prev Close	32.75
Employees	493	LT Debt/Eq	1.14	Earnings	May 07 BMO	SMA200	6.49%	Avg Volume	410.51K	Price	33.02
IPO	Feb 05, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	126.33% 8.56%	Trades		Volume	121,185	Change	0.82%

Date	Action	Analyst	Rating Change	Price Target Change
May-27-25	Initiated	Deutsche Bank	Buy	$65
Dec-13-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$74 → $35
Nov-11-24	Downgrade	Mizuho	Outperform → Neutral	$72 → $38
Oct-24-24	Initiated	UBS	Sell	$24
Oct-07-24	Downgrade	Guggenheim	Buy → Neutral
Apr-29-24	Initiated	Leerink Partners	Outperform	$74
Nov-20-23	Resumed	JP Morgan	Overweight	$60
Nov-02-23	Initiated	Cantor Fitzgerald	Overweight
Oct-31-23	Initiated	Robert W. Baird	Outperform	$84
Sep-13-23	Upgrade	JP Morgan	Neutral → Overweight	$9 → $22
Sep-13-23	Initiated	Needham	Buy	$75
Aug-16-23	Initiated	CapitalOne	Overweight	$84
Jul-17-23	Initiated	Canaccord Genuity	Hold	$67
Mar-31-23	Initiated	Mizuho	Buy	$70
Mar-30-23	Initiated	Guggenheim	Buy	$85
Mar-24-23	Initiated	Bryan Garnier	Buy	$16
Dec-16-22	Upgrade	Goldman	Neutral → Buy	$33 → $80
Nov-30-22	Initiated	Barclays	Overweight	$80
Sep-09-22	Initiated	Morgan Stanley	Overweight	$77
Sep-08-22	Initiated	Ladenburg Thalmann	Buy	$82

Show Previous Ratings

Jul-03-25 10:32AM	Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study (Zacks)
Jul-02-25 10:32AM	Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli (Zacks)
09:28AM	5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment (Zacks)
Jul-01-25 10:50AM	Biogen Begins Phase III Felzartamab Study for Third Kidney Disease (Zacks)
Jun-30-25 11:40AM	RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome (Zacks)
08:00AM	Loading…
08:00AM	Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS Regions (GlobeNewswire)
Jun-25-25 11:17AM	KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study (Zacks)
11:14AM	Strength Seen in Kamada (KMDA): Can Its 9.5% Jump Turn into More Strength? (Zacks)
11:06AM	Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU (Zacks)
10:02AM	Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag (Zacks)
Jun-24-25 11:58AM	CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular Indication (Zacks)
09:04AM	FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer (Zacks)
Jun-23-25 11:25AM	NVO Reports New Positive Phase III Data on Mim8 in Hemophilia A (Zacks)
09:53AM	FDA Extends INCY's Application for Opzelura Label Expansion (Zacks)
09:15AM	J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications (Zacks)
11:51AM	Loading…
Jun-20-25 11:51AM	CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech (Zacks)
Jun-17-25 12:08PM	Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics (Zacks)
12:02PM	Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy (Zacks)
10:30AM	AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study (Zacks)
Jun-16-25 08:45AM	SRPT Plummets on Second Patient Death After DMD Gene Therapy Infusion (Zacks) -5.10%
Jun-05-25 10:03AM	FDA Grants Platform Technology Tag to Sarepta's Gene Therapy Vector (Zacks)
Jun-03-25 11:53AM	TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises (Zacks)
11:41AM	FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch (Zacks)
Jun-02-25 09:55AM	Wall Street Analysts Think Immunocore (IMCR) Could Surge 65.22%: Read This Before Placing a Bet (Zacks) +5.60%
07:00AM	Immunocore to present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-25 09:29AM	Is it a Good Idea to Invest in Immunocore Stock Right Now? (Zacks)
May-16-25 09:55AM	Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High? (Zacks)
May-09-25 08:48AM	PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates (Zacks)
May-08-25 07:31AM	New Strong Buy Stocks for May 8th (Zacks)
May-07-25 12:09PM	ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down (Zacks) +6.63%
09:30AM	Loading…
09:30AM	Compared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key Metrics (Zacks)
08:59AM	BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates (Zacks)
07:40AM	CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks (Zacks)
07:00AM	Immunocore reports first quarter financial results and provides a business update (GlobeNewswire)
May-06-25 01:12PM	CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall (Zacks) -8.39%
11:59AM	VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened (Zacks)
09:39AM	AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y (Zacks)
May-02-25 11:10AM	Alkermes' Q1 Earnings and Revenues Fall Short of Estimates (Zacks)
07:53AM	Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates (Zacks)
Apr-30-25 09:55AM	Wall Street Analysts Think Immunocore (IMCR) Could Surge 107.45%: Read This Before Placing a Bet (Zacks)
09:07AM	Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y (Zacks)
Apr-27-25 09:22AM	Immunocore Holdings: A Name On My Watch List (Seeking Alpha)
Apr-02-25 11:49AM	Hospitals Experience FOMO In Adopting Delcath's PHP Treatment (Seeking Alpha)
08:00AM	Immunocore to present at upcoming investor conferences (GlobeNewswire)
Mar-25-25 10:46AM	Immunocore Holdings plc (IMCR): Among Stocks Receiving the Most Insider Love in March (InsiderMonkey)
Mar-21-25 10:21AM	Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last? (Zacks)
Mar-10-25 03:00PM	Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 (GlobeNewswire)
Mar-03-25 07:00AM	Immunocore to present at upcoming investor conferences (GlobeNewswire)
Feb-27-25 02:07AM	Immunocore Holdings PLC (IMCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
02:02AM	Q4 2024 Immunocore Holdings PLC Earnings Call (Thomson Reuters StreetEvents)
Feb-26-25 07:00AM	Immunocore reports fourth quarter and full year 2024 financial results and provides a business update (GlobeNewswire) +5.34%
Feb-25-25 10:32AM	Earnings To Watch: Immunocore Holdings PLC (IMCR) Reports Q4 2024 Result (GuruFocus.com)
Feb-20-25 03:00AM	Lillys former M&A chief scours the landscape for potential deals as Immunocores new CFO (Pharma Voice)
Feb-19-25 07:00AM	Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025 (GlobeNewswire)
Jan-13-25 09:55AM	Wall Street Analysts Believe Immunocore (IMCR) Could Rally 113.13%: Here's is How to Trade (Zacks)
Jan-10-25 07:00AM	Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-06-25 07:00AM	Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-25 07:00AM	Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (GlobeNewswire)
Dec-23-24 07:00AM	Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME (GlobeNewswire)
Dec-18-24 11:34AM	Immunocore doses first subject in gastrointestinal cancer therapy trial (Clinical Trials Arena)
Dec-17-24 07:00AM	Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers (GlobeNewswire)
Dec-13-24 02:10PM	Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? (Benzinga)
Dec-12-24 12:00PM	All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy (Zacks)
07:12AM	Immunocore, EORTC announce enrollment of first patient in Phase 3 ATOM trial (TipRanks)
Dec-11-24 07:00AM	EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma (GlobeNewswire)
Dec-03-24 01:00AM	Immunocore announces reimbursement agreement in England for KIMMTRAK? for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma (GlobeNewswire)
Nov-28-24 09:55AM	Does Immunocore (IMCR) Have the Potential to Rally 112.82% as Wall Street Analysts Expect? (Zacks)
Nov-19-24 08:58AM	Immunocore Holdings plc (IMCR): This Small-Cap Stock Is Ready To Explode (Insider Monkey)
Nov-18-24 08:25AM	Is Immunocore Holdings plc (IMCR) the Best Immunotherapy Stock to Buy Now? (Insider Monkey)
Nov-08-24 09:55AM	Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know (Zacks)
07:00AM	Immunocore to present at upcoming investor conferences (GlobeNewswire)
Nov-06-24 07:00AM	Immunocore reports third quarter financial results and provides a business update (GlobeNewswire)
Nov-05-24 12:00PM	Immunocore (IMCR) Upgraded to Buy: Here's Why (Zacks) +5.84%
Oct-09-24 05:31PM	Immunocore Holdings PLC (IMCR) Q2 2024 Earnings Call Highlights: Strong US Growth and Strategic ... (GuruFocus.com)
Sep-29-24 07:43AM	Immunocore Holdings plc (IMCR): Worst 52-Week Low Stock to Buy Now (Insider Monkey)
Sep-27-24 05:17AM	Immunocore Holdings plc (NASDAQ:IMCR) Ranks Low On The List Of Worst Falling Stocks To Buy (Insider Monkey)
Sep-25-24 11:29AM	Immunocore Holdings plc (IMCR) Hits 52-Week Low Despite 34% Surge in KIMMTRAK Sales (Insider Monkey)
Sep-14-24 05:12PM	Immunocore Holdings plc (IMCR): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
03:00AM	Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer (GlobeNewswire)
Sep-12-24 04:05PM	Immunocore to present at the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
01:30AM	Significant Portfolio Addition: T. Rowe Price Investment Management, Inc. ... (GuruFocus.com)
Sep-05-24 08:30AM	Immunocore Selects Genedata to Scale Up Discovery of Novel TCR Therapeutics (PR Newswire)
Aug-30-24 01:16AM	Immunocore Holdings plc (IMCR): Top ADR Stock According to Hedge Funds (Insider Monkey)
Aug-29-24 07:00AM	Immunocore announces transition of Chief Financial Officer (GlobeNewswire)
Aug-08-24 07:00AM	Immunocore reports second quarter financial results and provides a business update (GlobeNewswire)
Aug-06-24 10:41AM	3 Small-Cap Stocks with Significant Growth Potential (InvestorPlace)
Aug-01-24 07:00AM	Immunocore to report second quarter 2024 financial results and host call on August 8, 2024 (GlobeNewswire)
Jun-18-24 07:00AM	Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma (GlobeNewswire)
Jun-01-24 08:00AM	Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response (GlobeNewswire)
May-31-24 04:05PM	Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 (GlobeNewswire) -12.74%
May-30-24 04:00PM	Immunocore to present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-29-24 07:00AM	Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma (GlobeNewswire)
May-24-24 12:00PM	Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know. (Barrons.com)
May-08-24 01:54PM	IMCR Stock Earnings: Immunocore Hldgs Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
09:35AM	Immunocore Holdings' Shares Fall After Q1 Net Loss Widens (MT Newswires)
08:38AM	Immunocore Holdings PLC Reports Q1 2024 Earnings: Misses EPS Estimates, Surpasses Revenue Forecasts (GuruFocus.com)
07:00AM	Immunocore reports first quarter financial results and provides a business update (GlobeNewswire)
Apr-29-24 07:15AM	Leerink Partners Starts Immunocore Holdings With Outperform Rating, $74 Price Target (MT Newswires)
Apr-24-24 10:00AM	Immunocore announces upcoming presentation and posters at ASCO 2024 (GlobeNewswire)
Apr-04-24 04:00PM	Immunocore to present at upcoming investor conferences (GlobeNewswire)

Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX - Immune mobilizing monoclonal TCRs Against X disease. Its lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BAKER BROS. ADVISORS LP	Director	Mar 17 '25	Buy	29.72	807,338	23,993,224	2,144,060	Mar 19 06:40 PM
Brian Di Donato	affiliate	Mar 17 '25	Proposed Sale	30.00	100,000	3,000,000		Mar 17 04:24 PM
Brian Di Donato	affiliate	Mar 14 '25	Proposed Sale	29.13	56,250	1,638,511		Mar 14 05:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Immunocore Holdings plc ADR

Upgrade your FINVIZ experience